Nutra Pharma

Nutra Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Nutra Pharma (NPHC) as of Oct 23, 2026 is 58.12 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 32.98 % — a change of 76.26% (higher).

FCF Conversion

58.12 %

YoY

76.26%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nutra Pharma is 2025 58.12 % . FCF Conversion Rate (FCF/EBITDA) of Nutra Pharma was 2024 32.98 % . It decreases by 76.26% higher compared to the previous year.

The Nutra Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
25.89 USD
Jan 1, 2019
11.37 USD
Jan 1, 2020
11.37 USD
Jan 1, 2021
13.62 USD
Jan 1, 2022
-10.03 USD
Jan 1, 2023
39.48 USD
Jan 1, 2024
32.98 USD
Jan 1, 2025
58.12 USD
The Nutra Pharma FCF Conversion history
YEARFCF ConversionYoY
58.12 %+76.26%
32.98 %-16.47%
39.48 %-493.44%
-10.03 %-173.67%
13.62 %+19.76%
11.37 %0.00%
11.37 %-56.08%
25.89 %-9.09%
28.48 %-27.79%
39.44 %+108.74%
18.90 %+182.09%
6.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nutra Pharma Stock analysis

What does Nutra Pharma do? Nutra Pharma is an American biotechnology company specializing in researching, developing, and marketing medications for the treatment of neurological, autoimmune, and cancer diseases. The company was founded in 2000 and is headquartered in Coral Springs, Florida. Nutra Pharma initially focused on developing dietary supplements for joint pain and inflammation relief. However, in 2004, the company made a significant breakthrough with the introduction of Nyloxin, a natural pain reliever made from a unique combination of toxins from marine animals such as bees, snakes, and spiders. Nyloxin aims to provide a safe and effective alternative to conventional pain medications like ibuprofen and opioids. In addition to Nyloxin, Nutra Pharma also offers several other products including Sinus Buster, a nasal spray designed to alleviate headaches and migraines, and Pet Pain, a veterinary pain medication for pets. The company is also involved in the research and development of therapeutics for autoimmune diseases like multiple sclerosis and HIV. Nutra Pharma holds patents for its novel drugs and drug candidates, including its ReceptoPharm platform technology currently being utilized in Alzheimer's disease drug development. The company has built a wide network of distribution partners to market its products in the United States and other countries. It also employs an aggressive marketing strategy to raise awareness among physicians, pharmacists, veterinarians, and end consumers. Additionally, Nutra Pharma supports nonprofit organizations dedicated to researching and developing therapeutics for rare and incurable diseases. Overall, Nutra Pharma has become a significant player in the biotechnology industry, developing innovative products and technologies for pain, inflammation, and various diseases. The company has established itself as a valuable partner to distribution partners and nonprofit organizations, benefiting from its expertise and products. Nutra Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nutra Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Nutra Pharma is 58.12 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Nutra Pharma changed from 32.98 % to 58.12 %, representing a 76.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nutra Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nutra Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nutra Pharma

All Key Metrics — Nutra Pharma